TG Therapeutics stock spikes on strong financials and optimism for its flagship drug
The company's product for relapsing forms of multiple sclerosis (RMS), is its primary source of its most recent success
Joseph Morton
TG Therapeutics, Inc. NASDAQTGTX stock jumped 16 per cent on strong financial results, optimistic guidance and growing confidence in its flagship drug, Briumvi.
The company announced its financial results for the fourth quarter and the full year of 2024 before the market opened on Monday, and the numbers exceeded expectations.
TG reported a GAAP earnings per share (EPS) of USD$0.15 for Q4, paired with revenue of USD$108.19 million. These figures outperformed Wall Street estimates, signalling robust growth and operational success. For the full year, TG Therapeutics posted revenues of USD$310 million, reflecting a 250 per cent year-over-year increase.
Briumvi (ublituximab-xiiy), the company’s treatment for relapsing forms of multiple sclerosis (RMS), is the primary source of the company’s recent success. Launched in 2023, Briumvi has gained traction, with the company calling it the “fastest-growing MS drug” in its class. Sentiments on social media point out that Briumvi’s success positions TG Therapeutics as a rare biotech company generating significant profits.
Adding fuel to the fire, TG Therapeutics provided a positive outlook for the first quarter of 2025 during a Monday earnings call. Management expressed confidence in Briumvi’s continued momentum, citing accelerating new patient starts and an increasing share of repeat prescriptions.
The company’s guidance aligns with its broader 2025 business outlook. Analysts interpret this as a sign of confidence in capturing additional market share in the competitive MS treatment landscape.
Competitors like Roche SWXROG OTCMKTSRHHBY and Novartis AG NYSENVS dominate this space, but Briumvi’s unique profile as an anti-CD20 monoclonal antibody, combined with its rapid adoption, is carving out a niche for TG Therapeutics.
Read more: Breath Diagnostics onboards new president and closes critical financing
Read more: Breath Diagnostics pioneers novel lung cancer breath test
TG Therapeutics rise is also about recognition
Beyond the financials, TG Therapeutics shared encouraging clinical updates that further buoyed investor sentiment.
The company brought up a 92 per cent success rate in five-year data from its Phase 3 ULTIMATE I & II trials for Briumvi in RMS patients. This long-term efficacy data reinforces the drug’s value proposition and differentiates it in a crowded market.
However, the stock’s rise today isn’t just about numbers—it’s also about recognition.
TG Therapeutics was recently added to Investor’s Business Daily’s prestigious Leaderboard, a curated list of top-performing stocks.
Additionally, the company’s ability to deliver consistent revenue beats—exceeding its own 2024 guidance by 24 per cent, according to some analyses—has shifted perceptions from skepticism to optimism.
The social media sentiment is clear. TG Therapeutics is no longer seen as a speculative biotech but as a company with strong fundamentals and a clear growth trajectory.
However, some risks still exist.
While the outlook is overwhelmingly positive, TG Therapeutics remains a biotech stock, a sector known for volatility. With only one marketed product, Briumvi, the company’s fortunes are heavily tied to its performance. External factors such as inflation, regulatory changes, or competition could pose challenges.
